Cefaclor
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Cefaclor: From Bacterial Infections to Hyperamylasemia
One-Sentence Summary
Cefaclor is a second-generation oral cephalosporin antibiotic with established global use for treating bacterial infections including respiratory tract infections, urinary tract infections, and skin infections — though it currently holds no TGA registration in Australia.
The TxGNN model ranks Hyperamylasemia as the top predicted new indication; however, with no supporting clinical trials or publications, confidence in this prediction is very low (Evidence Level L5).
Analyst Note: The highest-evidence predicted indication within this evaluation pack is Gonococcal Urethritis (Rank 3, L3, 6 published studies). Clinicians reviewing this report for research prioritisation should refer to the gonococcal urethritis rationale in the Conclusion section.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bacterial infections (no TGA-approved indication; not registered in Australia) |
| Predicted New Indication | Hyperamylasemia |
| TxGNN Prediction Score | 97.70% |
| Evidence Level | L5 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on established pharmacological knowledge, Cefaclor is a second-generation cephalosporin that inhibits bacterial cell wall synthesis by covalently binding to penicillin-binding proteins (PBPs), blocking peptidoglycan cross-linking. Its chloro-substituted side chain — modified from cephalexin — provides improved Gram-negative coverage while retaining good oral bioavailability and gastrointestinal absorption.
Hyperamylasemia is a laboratory finding (elevated serum amylase) rather than a primary bacterial disease. Its most common causes — acute pancreatitis, salivary gland disorders, and intestinal injury — are non-infectious or metabolic in nature, with bacterial pathogens playing no direct causal role in amylase physiology. Cefaclor’s β-lactam mechanism has no pathway by which it could suppress amylase secretion, accelerate amylase clearance, or modify pancreatic enzyme activity.
The high TxGNN score (97.70%) is most plausibly explained by knowledge graph topology: acute infection is a recognised trigger of pancreatitis, placing the two concept nodes in close proximity within the knowledge graph. This graph adjacency does not constitute mechanistic or clinical rationale. Notably, the second-ranked prediction (polyclonal hyperviscosity syndrome) carries an identical score (0.9770268…), strongly suggesting a batch-computation artefact rather than genuine signal. This prediction should be treated as a graph false positive.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Cefaclor has no current TGA registration in Australia. For class-level safety reference, clinicians should consult prescribing information from an approved jurisdiction (e.g., FDA labelling or UK SPC). Well-established cephalosporin class considerations include: hypersensitivity reactions (including possible cross-reactivity in penicillin-allergic patients), Clostridioides difficile-associated diarrhoea with prolonged use, and dose adjustment requirements in renal impairment.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN prediction for hyperamylasemia has no supporting clinical evidence and no credible pharmacological mechanism. Cefaclor’s β-lactam mode of action cannot influence amylase secretion or clearance, and the identical scores across the top two predictions indicate this is a knowledge graph computation artefact rather than a genuine repurposing signal.
To proceed with any Cefaclor repurposing programme in Australia, the following is needed:
- TGA registration pathway assessment: Cefaclor currently has zero ARTG entries. Any clinical use in Australia would require either a full ARTG submission or access via the TGA Special Access Scheme (SAS) or Authorised Prescriber pathway.
- Redirect evaluation effort to Gonococcal Urethritis (Rank 3): This is the only indication with biologically credible mechanism and actual evidence in this pack — Neisseria gonorrhoeae expresses PBP1/PBP2 targets, and six published studies (including controlled clinical trials, 1979–1997) documented Cefaclor efficacy. Before any clinical consideration, current local antimicrobial resistance patterns must be assessed: WHO and CDC guidelines now recommend ceftriaxone 500 mg IM as standard of care due to widespread oral cephalosporin resistance.
- Local MIC surveillance: Current minimum inhibitory concentration (MIC) data for Australian N. gonorrhoeae strains is essential before any contemplation of Cefaclor for gonococcal infection.
- Full MOA data retrieval: Retrieve complete mechanism of action, pharmacokinetic, and target data from DrugBank (DB00833) to support formal mechanistic analysis.
- Safety data: Source TGA-equivalent warnings, contraindications, and drug interaction data from an approved jurisdiction’s Product Information (PI) prior to any prescribing or research protocol development.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.